Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data.
Solish N, Ascher B, Avelar RL, Bertucci V, Bodokh I, Carruthers J, Cartier H, Delmar H, Denfeld R, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Rzany BJ, Sattler G, Sebastian M, Swift A, Trévidic P. Solish N, et al. Among authors: bodokh i. Aesthet Surg J. 2022 Dec 14;42(12):1460-1469. doi: 10.1093/asj/sjac210. Aesthet Surg J. 2022. PMID: 35922149 Free PMC article. Clinical Trial.
Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, Noah EM, Boineau D, Kerscher M, Volteau M, Le Berre P, Picaut P. Ascher B, et al. Among authors: bodokh i. Aesthet Surg J. 2021 Oct 15;41(11):1338. doi: 10.1093/asj/sjab111. Aesthet Surg J. 2021. PMID: 33739363 Free PMC article. No abstract available.
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial.
Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, Noah EM, Boineau D, Kerscher M, Volteau M, Le Berre P, Picaut P. Ascher B, et al. Among authors: bodokh i. Aesthet Surg J. 2020 Aug 14;40(9):1000-1008. doi: 10.1093/asj/sjz248. Aesthet Surg J. 2020. PMID: 31550352 Free PMC article. Clinical Trial.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ, Ascher B, Avelar RL, Bergdahl J, Bertucci V, Bodokh I, Carruthers JA, Cartier H, Delmar H, Denfeld R, Gross JE, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Sattler G, Sebastian M, Solish N, Swift A, Trévidic P. Rzany BJ, et al. Among authors: bodokh i. Aesthet Surg J. 2020 Mar 23;40(4):413-429. doi: 10.1093/asj/sjz110. Aesthet Surg J. 2020. PMID: 30951166 Clinical Trial.
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
Ascher B, Rzany B, Kestemont P, Hilton S, Heckmann M, Bodokh I, Noah EM, Boineau D, Kerscher M, Volteau M, Le Berre P, Picaut P. Ascher B, et al. Among authors: bodokh i. Aesthet Surg J. 2020 Jan 1;40(1):93-104. doi: 10.1093/asj/sjz003. Aesthet Surg J. 2020. PMID: 30893430 Free PMC article. Clinical Trial.
Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.
Ascher B, Kestemont P, Boineau D, Bodokh I, Stein A, Heckmann M, Dendorfer M, Pavicic T, Volteau M, Tse A, Picaut P, Rzany B. Ascher B, et al. Among authors: bodokh i. Aesthet Surg J. 2018 Feb 17;38(2):183-191. doi: 10.1093/asj/sjw272. Aesthet Surg J. 2018. PMID: 28200002 Clinical Trial.
49 results